Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer

Christina L. Roland, Anthony D. Yang, Matthew H G Katz, Deyali Chatterjee, Huamin Wang, Heather Lin, Jean N. Vauthey, Peter W. Pisters, Gauri R. Varadhachary, Robert A. Wolff, Christopher H. Crane, Jeffrey E. Lee, Jason B. Fleming

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background: The use of neoadjuvant therapy (NAC) for the treatment of potentially resectable pancreatic cancer remains controversial. In this study, we sought to evaluate cancer-specific endpoints in patients undergoing a NAC versus a surgery-first (SF) approach with specific emphasis on lymph node metastases. Methods: A total of 222 patients who underwent NAC and 85 patients who underwent SF were identified from 1990 to 2008 and compared for cancer-related endpoints. Peripancreatic lymph nodes from 135 neoadjuvant therapy patients were evaluated for histologic tumor regression. Results: Patients who underwent NAC followed by surgery had improved overall survival and time to local recurrence compared with the SF approach. NAC patients were less likely to have lymph node metastases (p = 0.001), lymphovascular invasion (LVI), and had smaller tumors. On multivariate analysis, lymph node positivity was associated with SF, tumor size, and the presence of LVI. NAC patients with N0 disease had equivalent outcomes to patients with a low-LNR (0.01–0.15), whereas patients with a LNR >0.15 had reduced survival, and time to local and distant recurrence. Ten of 135 (7.4 %) NAC patients had evidence of tumor regression in at least one lymph node. Conclusions: Patients with potentially resectable PDAC selected to undergo NAC had improved survival and longer time to recurrence. Although some of these differences may be related to improvements in multimodality therapy completion rates, tumor regression in lymph node metastases exists and may demonstrate a biologic benefit of NAC compared with a SF approach.

Original languageEnglish (US)
Pages (from-to)1168-1175
Number of pages8
JournalAnnals of Surgical Oncology
Volume22
Issue number4
DOIs
StatePublished - 2015

Fingerprint

Neoadjuvant Therapy
Pancreatic Neoplasms
Lymph Nodes
Neoplasms
Neoplasm Metastasis
Recurrence
Survival
Multivariate Analysis

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Roland, C. L., Yang, A. D., Katz, M. H. G., Chatterjee, D., Wang, H., Lin, H., ... Fleming, J. B. (2015). Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer. Annals of Surgical Oncology, 22(4), 1168-1175. https://doi.org/10.1245/s10434-014-4192-6

Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer. / Roland, Christina L.; Yang, Anthony D.; Katz, Matthew H G; Chatterjee, Deyali; Wang, Huamin; Lin, Heather; Vauthey, Jean N.; Pisters, Peter W.; Varadhachary, Gauri R.; Wolff, Robert A.; Crane, Christopher H.; Lee, Jeffrey E.; Fleming, Jason B.

In: Annals of Surgical Oncology, Vol. 22, No. 4, 2015, p. 1168-1175.

Research output: Contribution to journalArticle

Roland, CL, Yang, AD, Katz, MHG, Chatterjee, D, Wang, H, Lin, H, Vauthey, JN, Pisters, PW, Varadhachary, GR, Wolff, RA, Crane, CH, Lee, JE & Fleming, JB 2015, 'Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer', Annals of Surgical Oncology, vol. 22, no. 4, pp. 1168-1175. https://doi.org/10.1245/s10434-014-4192-6
Roland, Christina L. ; Yang, Anthony D. ; Katz, Matthew H G ; Chatterjee, Deyali ; Wang, Huamin ; Lin, Heather ; Vauthey, Jean N. ; Pisters, Peter W. ; Varadhachary, Gauri R. ; Wolff, Robert A. ; Crane, Christopher H. ; Lee, Jeffrey E. ; Fleming, Jason B. / Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer. In: Annals of Surgical Oncology. 2015 ; Vol. 22, No. 4. pp. 1168-1175.
@article{c8bfb852685e41ffa7b71a785b36023c,
title = "Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer",
abstract = "Background: The use of neoadjuvant therapy (NAC) for the treatment of potentially resectable pancreatic cancer remains controversial. In this study, we sought to evaluate cancer-specific endpoints in patients undergoing a NAC versus a surgery-first (SF) approach with specific emphasis on lymph node metastases. Methods: A total of 222 patients who underwent NAC and 85 patients who underwent SF were identified from 1990 to 2008 and compared for cancer-related endpoints. Peripancreatic lymph nodes from 135 neoadjuvant therapy patients were evaluated for histologic tumor regression. Results: Patients who underwent NAC followed by surgery had improved overall survival and time to local recurrence compared with the SF approach. NAC patients were less likely to have lymph node metastases (p = 0.001), lymphovascular invasion (LVI), and had smaller tumors. On multivariate analysis, lymph node positivity was associated with SF, tumor size, and the presence of LVI. NAC patients with N0 disease had equivalent outcomes to patients with a low-LNR (0.01–0.15), whereas patients with a LNR >0.15 had reduced survival, and time to local and distant recurrence. Ten of 135 (7.4 {\%}) NAC patients had evidence of tumor regression in at least one lymph node. Conclusions: Patients with potentially resectable PDAC selected to undergo NAC had improved survival and longer time to recurrence. Although some of these differences may be related to improvements in multimodality therapy completion rates, tumor regression in lymph node metastases exists and may demonstrate a biologic benefit of NAC compared with a SF approach.",
author = "Roland, {Christina L.} and Yang, {Anthony D.} and Katz, {Matthew H G} and Deyali Chatterjee and Huamin Wang and Heather Lin and Vauthey, {Jean N.} and Pisters, {Peter W.} and Varadhachary, {Gauri R.} and Wolff, {Robert A.} and Crane, {Christopher H.} and Lee, {Jeffrey E.} and Fleming, {Jason B.}",
year = "2015",
doi = "10.1245/s10434-014-4192-6",
language = "English (US)",
volume = "22",
pages = "1168--1175",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer

AU - Roland, Christina L.

AU - Yang, Anthony D.

AU - Katz, Matthew H G

AU - Chatterjee, Deyali

AU - Wang, Huamin

AU - Lin, Heather

AU - Vauthey, Jean N.

AU - Pisters, Peter W.

AU - Varadhachary, Gauri R.

AU - Wolff, Robert A.

AU - Crane, Christopher H.

AU - Lee, Jeffrey E.

AU - Fleming, Jason B.

PY - 2015

Y1 - 2015

N2 - Background: The use of neoadjuvant therapy (NAC) for the treatment of potentially resectable pancreatic cancer remains controversial. In this study, we sought to evaluate cancer-specific endpoints in patients undergoing a NAC versus a surgery-first (SF) approach with specific emphasis on lymph node metastases. Methods: A total of 222 patients who underwent NAC and 85 patients who underwent SF were identified from 1990 to 2008 and compared for cancer-related endpoints. Peripancreatic lymph nodes from 135 neoadjuvant therapy patients were evaluated for histologic tumor regression. Results: Patients who underwent NAC followed by surgery had improved overall survival and time to local recurrence compared with the SF approach. NAC patients were less likely to have lymph node metastases (p = 0.001), lymphovascular invasion (LVI), and had smaller tumors. On multivariate analysis, lymph node positivity was associated with SF, tumor size, and the presence of LVI. NAC patients with N0 disease had equivalent outcomes to patients with a low-LNR (0.01–0.15), whereas patients with a LNR >0.15 had reduced survival, and time to local and distant recurrence. Ten of 135 (7.4 %) NAC patients had evidence of tumor regression in at least one lymph node. Conclusions: Patients with potentially resectable PDAC selected to undergo NAC had improved survival and longer time to recurrence. Although some of these differences may be related to improvements in multimodality therapy completion rates, tumor regression in lymph node metastases exists and may demonstrate a biologic benefit of NAC compared with a SF approach.

AB - Background: The use of neoadjuvant therapy (NAC) for the treatment of potentially resectable pancreatic cancer remains controversial. In this study, we sought to evaluate cancer-specific endpoints in patients undergoing a NAC versus a surgery-first (SF) approach with specific emphasis on lymph node metastases. Methods: A total of 222 patients who underwent NAC and 85 patients who underwent SF were identified from 1990 to 2008 and compared for cancer-related endpoints. Peripancreatic lymph nodes from 135 neoadjuvant therapy patients were evaluated for histologic tumor regression. Results: Patients who underwent NAC followed by surgery had improved overall survival and time to local recurrence compared with the SF approach. NAC patients were less likely to have lymph node metastases (p = 0.001), lymphovascular invasion (LVI), and had smaller tumors. On multivariate analysis, lymph node positivity was associated with SF, tumor size, and the presence of LVI. NAC patients with N0 disease had equivalent outcomes to patients with a low-LNR (0.01–0.15), whereas patients with a LNR >0.15 had reduced survival, and time to local and distant recurrence. Ten of 135 (7.4 %) NAC patients had evidence of tumor regression in at least one lymph node. Conclusions: Patients with potentially resectable PDAC selected to undergo NAC had improved survival and longer time to recurrence. Although some of these differences may be related to improvements in multimodality therapy completion rates, tumor regression in lymph node metastases exists and may demonstrate a biologic benefit of NAC compared with a SF approach.

UR - http://www.scopus.com/inward/record.url?scp=84925496322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925496322&partnerID=8YFLogxK

U2 - 10.1245/s10434-014-4192-6

DO - 10.1245/s10434-014-4192-6

M3 - Article

C2 - 25352267

AN - SCOPUS:84925496322

VL - 22

SP - 1168

EP - 1175

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -